Artelo Biosciences, Inc.
ARTL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001621221
No open-market purchases or sales by Artelo Biosciences, Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $132.0K in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Artelo Biosciences, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 7 | 6 | −1 |
| Shares | 24.9K | 25.7K | +876 (+3.5%) |
| Value | $37.2K | $35.7K | −$1.51K (−4.1%) |
New holders (2)
Institutions that held Artelo Biosciences, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citigroup Inc | 46 | $64 | 0.00% |
| Bank of America Corp | 26 | $35 | 0.00% |
Sold out (3)
Institutions that held Artelo Biosciences, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| UBS Group AG | 125 | $185 |
| Wells Fargo & Company | 25 | $37 |
| GWM Advisors LLC | 1 | $1 |